title: [Experimental therapy in HCV infection].
abstract: PEGInterferon and ribavirin combination therapy is a gold standard in hepatitis C treatment. However it is not efficacious in all cases. Therefore, many studies are conducted to identifying additional drugs and therapeutic regimens, which might be more affordable. The progress in development of HCV culture systems (e.g.replicon) is crucial for successful therapeutic intervention in viral life-cycle (viral NS5B polymerase and NS3/4A protease inhibitors, antisense nucleotides, ribozymes, siRNA). Other classes of immunomodulatory/antiviral agents and new interferon formulation have also been considered for IFN-based therapy also. On the other hand immunomodulatory pathways are attractive target for novel anti-HCV therapy. Combination therapy targeting different aspects will be probably in the future successful option in hepatitis C treatment.
authors.affiliation: Katedra i Klinika Chorób Zakaźnych, Chorób Watroby i Nabytych Niedoborów Odpornościowych AM we Wrocławiu.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Inglot
authors.forename: Andrzej
authors.initials: A
authors.lastname: Gładysz
authors.forename: Weronika
authors.initials: W
authors.lastname: Rymer
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011092:Polyethylene Glycols; D011753:Pyrones / Q000378:metabolism; D016337:RNA, Catalytic / Q000627:therapeutic use; D034741:RNA, Small Interfering / Q000627:therapeutic use; D012367:RNA, Viral / Q000037:antagonists & inhibitors*; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011753:Pyrones; D016337:RNA, Catalytic; D034741:RNA, Small Interfering; D012367:RNA, Viral; D011994:Recombinant Proteins; D017361:Viral Nonstructural Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D012324:RNA-Dependent RNA Polymerase; C417083:peginterferon alfa-2b